Report #2824526

Received Feb 4, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: TX
Recovered: Unknown
Vaccinated: Aug 24, 2024
Onset: Sep 29, 2024
Days to onset: 36
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	943008	IM / LA

Symptoms (2)

Interchange of vaccine productsNo adverse event

Symptom narrative

First Dose Heplisav-B, Second Dose Twinrix; Initial report received on 03-Jan-2025. A pharmacist reported that a 59-year-old (race, ethnicity not reported) received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization and then received TWINRIX as the second dose of the series. No medical history or concomitant medications were reported. On 24-Aug-2024, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot # 943008, expiration 30-Sep-2025, NDC # 43528-0003-05) intramuscularly in the left deltoid. On 29-Sep-2024, the patient received a dose of TWINRIX (hepatitis A/hepatitis B vaccine). Reporter stated that no adverse effects were reported. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.